Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 2, 2015, Pages 417-423

  Matulonis, Ursula ^a   Berlin, Suzanne ^a   Lee, Hang ^b   Whalen, Christin ^a   Obermayer, Elizabeth ^a   Penson, Richard ^b   Liu, Joyce ^a   Campos, Susana ^a   Krasner, Carolyn ^b   Horowitz, Neil ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HDAC inhibitors; Ovarian cancer; Platinum sensitive; Vorinostat

Indexed keywords

CARBOPLATIN; GEMCITABINE; VORINOSTAT; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; HYDROXAMIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; LEUKOCYTE COUNT; LUNG EMBOLISM; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPHIL COUNT; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; SIDE EFFECT; SKIN BRUISING; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FALLOPIAN TUBE NEOPLASMS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DEOXYCYTIDINE; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; HYDROXAMIC ACIDS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84938423777     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2813-9     Document Type: Article

References (28)

1. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics 2014. CA Cancer J Clin 64:9-29
2. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419-1425
3. McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6
4. Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine/carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO OVAR, NCIC CTG and EORTC GCG. J Clin Oncol 24:4699-4706
5. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M et al (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28:3323-3329
6. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al (2012) Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. NEJM 366:1382-1392
7. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III study of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039-2045
8. Richon VM, Garcia-Vargas J, Hardwick JS (2009) Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 280:201-210
9. Takai N, Kawamata N, Gui D et al (2004) Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 21:2760-2770
10. Sonnemann J, Gange J, Pilz S et al (2006) Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6:183
11. Cooper AL, Greenberg VL, Lancaster PS et al (2007) In vitro and in vivo histone deacetylase inhibitor activity with SAHA and paclitaxel in ovarian cancer. Gynecol Oncol 104:596-601
12. Nolan L, Johnson PWM, Ganesan A et al (2008) Will histone deacetylase inhibitors require combination with other agents to fulfill their therapeutic potential? Br J Cancer 99:689-694
13. Kim MS, Blake M, Baek JH et al (2003) Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63:7291-7300
14. Fantin VR, Richon VM (2007) Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 13:7237-7242
15. Kelly WK, Marks PA (2005) Drug insight: histone deacetylase inhibitors - development of a new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Prac Oncol 2:150-157
16. Gabrielli B, Warrener R, Burgess A et al (1030) Defining the chemotherapeutic targets of histone deacetylase inhibitors. Ann NY Acad Sci 2004:627-635
17. Modesitt SC, Sill M, Hoffman JS et al (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109:182-186
18. Mackay HJ, Hirte H, Colgan T, Covens A, MacAlpine K, Grenci P et al (2010) Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) tumors. Eur J Cancer 46:1573-1579
19. Therasse P, Arbuck S et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. FDA package insert for gemcitabine for relapsed ovarian cancer. http://www.gemzar.com. Accessed 22 June 2015
21. Mendevil AA, Micha JP, Brown JV, Rettenmaier MA, Abaid LN et al (2013) Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced stage epithelial ovarian, primary peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 23:533-539
22. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M et al (2010) Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non small cell lung cancer. J Clin Oncol 28:56-62
23. Tredaniel J, Descourt R, Moro-Sibilot D, Misset J, Gachard E et al (2009) Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer: a phase I dose escalation study. J Clin Oncol 27:15s (suppl; abstr 8049)
24. Dizon DS, Blessing JA, Penson RT, Drake RD, Walker JL et al (2012) A phase II of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 125:367-371
25. du Bois A, Luck HJ, Pfisterer J et al (2001) Second line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose finding study by the Arbeitgemeinschaft Gynakologische (AGO) ovarian cancer study group. Ann Oncol 12:1115-1120
26. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL et al (2014) Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15:852-861
27. Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D (2014) Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Gynecol Oncol 133:599-606
28. Sato A, Asano T, Ito K, Sumitomo M, Asano T (2011) Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. Br J Urol 109:1258-1268